18 April 2018
A delegation of eight Catalan companies from the biomedicine and health arena, most CataloniaBio & HealthTech members, participated in a business mission to Toronto (Canada) from 9 to 13 April to scout for new clients, partners and investors in one of the most advanced ecosystems in the world.
The mission —organised by ACCIÓ in collaboration with the Canadian consulate in Barcelona, Biocat and the Canadian ToHealth cluster— featured Adan Medical Innovation, Ahead Therapeutics, Althaia, INTERmedic, Inveready, Laboratorios Rubió, Mind the Byte and Reig Jofre.
The business mission coincided with Toronto Health Innovation Week (THIW), which offered more than 30 activities ...
12 April 2018
Reig Jofre has announced a €30 million investment and the triplication of the productive capacity of its Barcelona plant. The pharmaceutical group, a member of CataloniaBio & HealthTech, informs the project will imply the construction of a new building provided with state-of-the-art technologies for the manufacture of lyophilized vials and liquid vials.
It will also increase the aseptic production capacity, and will enable addressing the development and manufacture of innovative and biosimilars products (it has created the joint venture Syna Therapeutics with the biotechnology company Leanbio).
The new building for liquid and freeze-dried vials will be built inside ...
11 April 2018
The QFast® products are developed using a technology platform to detect and identify biological pathogens (salmonella, E. Coli, etc.) designed as an integrated system.
This agreement between the companies aims to promote commercial development and provide quality technical service.
11 April 2018
AB-Biotics, a CataloniaBio & HealthTech member company, has closed a deal with the Japan-based Kaneka Corporation that will give them exclusive rights in Japan and the United States. In exchange, AB-Biotics will take a percentage of the business generated in these markets.
This makes Kaneka Corporation the Catalan biotechnology firm’s largest shareholder, acquiring 34% of shares. The AB-Biotics founding partners, Miquel Àngel Bonachera and Sergi Audivert, are the second shareholders, with a 20.22% joint stake. Bonachera and Audivert noted that the operation will allow them to “accelerate growth over the coming years, with a top-notch strategic partner.” ...
10 April 2018
Vytrus Biotech, a CataloniaBio & HealthTech member company, has successfully closed the €1-million round of funding it began in the fourth quarter of 2017.
This injection of funds will allow the company to continue its expansion strategy, which includes going public on the Spanish Alternative Stock Exchange (Mercado Alternativo Bursátil - MAB) in 2019. After this increase, the company now has approximately 200 shareholders.
Vytrus Biotech was created in 2009 in Terrassa by entrepreneurs Albert Jané and Óscar Expósito as a spin-off of the University of Barcelona Faculty of Pharmacy. The company’s business is based on plant biotechnology and stem cells ...
6 April 2018
Devicare and nine leading hospitals in urology have started the pioneering international "Double J" study to evaluate the combined use of a medical device and a nutraceutical in controlling urinary pH and inhibiting crystallisation in order to prevent the calcification of double J stent catheters and reduce the number of associated complications. Each year 90,000 double J stent catheters are implanted in Spain, approximately 25% of which lead to complications.
"The calcification of a double J stent catheter implant can make surgical extraction complex, while when there are no encrustations it is an operation that lasts a few ...
6 April 2018
Multinational company Grifols, member of CataloniaBio & HealthTech, makes inroads in its research efforts to find a treatment for Alzheimer's disease. The patients enrolled in the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial have finished treatment. Thus ends the experimental phase of the trial, giving way to data collection and evaluation and analysis of the results, which the company plans to announce in the fourth quarter of 2018.
AMBAR is an international and multi-center clinical trial that included 496 patients with mild to moderate Alzheimer's disease across 41 hospitals (20 in Spain and 21 in the United States). Among ...
5 April 2018
Pharmaphenix, member of CataloniaBio & HealthTech and headquartered in the Barcelona Science Park, is celebrating its 10th anniversary. During this past decade, the consulting company has firmly positioned itself as a benchmark in emerging Latin American, Middle Eastern, South Korean, Russian and Australian markets.
In 2008, Pascal Nizet, founding partner in Spain with an extensive experience in leadership positions in the pharmaceutical industry, set up Pharmaphenix to advise healthcare companies in addressing new markets and driving their growth through expansion abroad.
Its Seoul headquarters is also celebrating its 10th anniversary, while the firm additionally has a number of ...
26 March 2018
26 March 2018
The pharmaceutical company Reig Jofre strengthens its commitment to open innovation and the development of injectable and freeze-dried products with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules.